# NCT03013998 (NCT03013998)

> Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03013998
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: Beat AML, LLC
- Conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
- Interventions: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2); Laboratory Biomarker Analysis; Daunorubicin (BAML-16-001-S1); Cytarabine (BAML-16-001-S1); Azacitidine (BAML-16-001-S2); AG-221 (BAML-16-001-S3); Azacitidine (BAML-16-001-S3); Entospletinib (BAML-16-001-S4); Azacitidine (BAML-16-001-S4); Entospletinib (BAML-16-001-S5); Decitabine (BAML-16-001-S5); Entospletinib (BAML-16-001-S6); Daunorubicin (BAML-16-001-S6); Cytarabine (BAML-16-001-S6); Pevonedistat (BAML-16-001-S9); Azacitidine (BAML-16-001-S9); AG-120 (BAML-16-001-S16); Azacitidine (BAML-16-001-S16); Gilteritinib (BAML-16-001-S8 Group 1); Decitabine (BAML-16-001-S8 Group 1); AZD5153 (BAML-16-001-S10); Venetoclax (BAML-16-001-S10); TP-0903 (BAML-16-001-S14); Decitabine (BAML-16-001-S14); Decitabine (BAML-16-001-S8 Group 2); Venetoclax (BAML-16-001-S8 Group 2); AZD5991 (BAML-16-001-S18); Azacitidine (BAML-16-001-S18); SNDX-5613 (BAML-16-001-S17); Azacitidine (BAML-16-001-S17); Venetoclax (BAML-16-001-S17); Gilteritinib (BAML-16-001-S8 Group 2); Venetoclax (BAML-16-001-S12 Arm A); Azacitidine (BAML-16-001-S12 Arm A); Venetoclax (BAML-16-001-S12 Arm B); Azacitidine (BAML-16-001-S12 Arm B); ZE46-0134 (BAML-16-001-S21 Group 1); ficlatuzumab (BAML-16-001-S24); Azacitidine (BAML-16-001-S24); Venetoclax (BAML-16-001-S24); ZE46-0134 (BAML-16-001-S21 Group 2); Bleximenib (BAML-16-001-S25/HO181); Cytarabine (BAML-16-001-S25/HO181); Daunorubicin or Idarubicin (BAML-16-001-S25/HO181); Placebo (BAML-16-001-S25/HO181); Revumenib (BAML-16-001-S26/HO177); Placebo (BAML-16-001-S26/HO177)
- Enrollment: 3000
- Primary outcome: BAML-16-001-M1: Proportion of patients for whom molecular, immunophenotypic, and/or biochemical studies are completed in < 7 calendar days for assignment of treatment
- Primary outcome: BAML-16-001-M1: Proportion of patients assigned to a novel therapeutic treatment group in 1 of several sub-studies in this Master Protocol, based on the result of the molecular, immunophenotypic, and/or biochemical studies
- Primary outcome: BAML-16-001-M1: Clinical response rate (rate of complete and partial responses) according to European Leukemianet (ELN) criteria for treatment outcomes in substudies in acute myeloid leukemia.
- Primary outcome: BAML-16-001-S25/HO181: Event-Free Survival (EFS) in adult patients with newly diagnosed NPM1m or KMT2Ar AML eligible for intensive chemotherapy
- Primary outcome: BAML-16-001-S26/HO177: Overall survival (OS) in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapy.
- Primary outcome: BAML-16-001-S26/HO177: Rate of CR in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapy

## Indexed commentary on NCT03013998 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03013998